Crofelemer

Drug Profile

Crofelemer

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002; Virend

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Glenmark Pharmaceuticals Ltd; Napo Pharmaceuticals; Shaman Pharmaceuticals
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 31 Jan 2017 Phase-I clinical trials in chemotherapy induced Diarrhoea (Prevention) in USA (PO) (NCT02910219)
  • 04 Oct 2016 Georgetown University, in collaboration with Napo Pharmaceuticals and Genentech plans a phase II trial for chemotherapy induced Diarrhoea (in patients with HER 2 positive Breast Cancer) in USA (NCT02910219)
  • 07 Mar 2016 Napo Pharmaceuticals terminates its licence for crofelemer in North America, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top